A Human iPSC-Based Lung Organoid with Stromal and Macrophage Components for Pulmonary Fibrosis Modelling and Pharmacological Response Assessment
This study establishes a reconstructable human multicellular lung organoid model (hiLOFM) incorporating stromal and macrophage components that effectively mimics the complex pathophysiology of pulmonary fibrosis and enables the assessment of pharmacological responses to both established antifibrotics and novel therapeutics.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human lung is a delicate, branching network designed to move oxygen into the blood and carbon dioxide out. When this system works, it is invisible to us. But when the lung tissue becomes scarred and stiff, a condition known as pulmonary fibrosis, breathing becomes a struggle. This scarring is not just a simple blockage; it is a complex biological failure where the lung's structural support cells overgrow, and the immune system gets stuck in a loop of inflammation that damages healthy tissue. For decades, scientists have tried to study this disease in test tubes or in mice, but these models often fail to capture the full, messy reality of human biology. Mice do not develop the disease in the same way humans do, and simple cell cultures lack the diverse team of cells that interact to cause the damage. To truly understand how to stop the scarring or how new drugs might affect the lung, researchers need a model that behaves more like a human lung, complete with its different cell types working together in a shared environment.
A team of researchers has built such a model, creating a tiny, three-dimensional lung structure in a dish that mimics the cellular complexity of the human body. They started with human induced pluripotent stem cells, which are versatile cells that can be guided to become almost any type of tissue. From these, they grew lung organoids, which are miniature, self-organizing clusters of lung cells. However, a lung organoid on its own is only part of the story. To make the model realistic, the scientists added two other critical components: human fibroblasts, which are the cells responsible for building the lung's structural framework, and macrophages, a type of immune cell that patrols the tissue. They combined these three elements in a specific ratio, creating a tri-culture system where the lung cells, the structural builders, and the immune sentinels could interact naturally. This new system, which the researchers call a lung organoid-fibroblast-macrophage model, allows them to watch how these different cell types talk to each other when the lung is under attack.
The researchers first tested whether this model could actually mimic the disease. They exposed the tiny lung structures to specific chemical signals known to trigger inflammation and scarring. In a healthy lung, these signals would be managed and resolved. In their model, the presence of all three cell types led to a dramatic response. The fibroblasts transformed into aggressive, scar-making cells, and the immune cells released signals that amplified the damage. The entire structure changed shape, becoming denser and more compact, much like a lung that is slowly turning to stone. Crucially, the model showed that the immune cells played a unique role; when the macrophages were present, the scarring response was stronger and more complex than when the lung cells and fibroblasts were alone. This confirmed that the immune system is a key driver in the disease process, and that a model lacking these cells would miss a vital part of the picture.
Once they proved the model could replicate the disease, the team used it to test how well it could predict the effects of medicine. They treated the scarred lung structures with two drugs already approved for treating pulmonary fibrosis in humans, known as nintedanib and pirfenidone. When these drugs were added to the model, the aggressive scarring response slowed down. The cells produced less of the proteins that cause stiffness, and the structures began to look slightly more like healthy lung tissue again. The model was sensitive enough to show that a combination of both drugs worked better than either one alone, reducing the scarring markers more effectively. This suggests that the model can be used to screen new treatments, helping scientists see if a drug will work before it is ever tested on a person.
The researchers also used the model to investigate a different kind of risk: drug-induced lung injury. They tested a powerful cancer drug called DS-8201, which is known to sometimes cause severe lung inflammation and scarring as a side effect. When they exposed their lung model to this drug, the cells reacted in a way that mirrored the side effects seen in patients. The drug triggered inflammation, altered the behavior of the lung cells, and encouraged the formation of scar tissue, even at low concentrations. The model detected these harmful signals across multiple different measurements, showing that it could spot potential lung toxicity early. This capability is vital for the pharmaceutical industry, as it offers a way to catch dangerous side effects during the development phase, potentially saving patients from severe harm later on.
Throughout the study, the researchers ensured that their model was robust and repeatable. They showed that the lung organoids could be grown, frozen, and thawed without losing their ability to function, and that they could be expanded over many generations. This means the model is not a one-time experiment but a reliable tool that can be used repeatedly to test different drugs or conditions. By combining expandable stem-cell-derived lung tissue with defined populations of immune and structural cells, the team has created a platform that bridges the gap between simple cell cultures and complex animal studies. While the model does not perfectly replicate every mechanical aspect of a breathing lung, it successfully captures the essential cellular conversations that drive fibrosis. This work provides a clearer window into how human lungs respond to injury and treatment, offering a practical tool to accelerate the search for better therapies and safer medicines.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.